Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Johnson and Johnson
Healthtrust
Fish and Richardson
Boehringer Ingelheim
Covington
McKesson
Accenture
QuintilesIMS
Federal Trade Commission

Generated: May 27, 2018

DrugPatentWatch Database Preview

Claims for Patent: 5,135,950

« Back to Dashboard

Summary for Patent: 5,135,950
Title: Stable polymorphic form of (E)-N,N-diethyl-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)acrylamide and the process for its preparation
Abstract:Stable and crystallographically essentially pure polymorphic form A of (E)-N,N-diethyl-2-cyano-3-(3,4-dihydroxy-5-nitro-phenyl)acrylamide may be prepared by crystallizing crude synthesis product from lower aliphatic carboxylic acid such as formic or acetic acid with a catalytic amount of hydrochloric or hydrobromic acid added. The product is a potent inhibitor of catechol-O-methyl-transferase enzyme (COMT).
Inventor(s): Pippuri; Aino K. (Espoo, FI), Honkanen; Erkki J. (Vantaa, FI), Haarala; Jorma V. (Helsinki, FI)
Assignee: Orion-yhtyma Oy (Espoo, FI)
Application Number:07/606,717
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 5,135,950
Patent Claims: 1. The crystallographically essentially pure polymorphic form A of (E)-N,N-diethyl-2-cyano-3-(3,4dihydroxy-5-nitrophenyl)acrylamide having the infrared spectrum in potassium bromide having the following absorption bands:

2. A process for preparing crystallographically essentially pure polymorphic form A of (E)-N,N-diethyl-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl) acrylamide having the infrared spectrum in potassium bromide having the following absorption bands:

which comprises crystallization of the crude N,N-diethyl-2-cyano-3-(3,4-dihydroxy -5-nitrophenyl acrylamide from lower aliphatic carboxylic acid containing a catalytic amount of hydrochloric or hydrobromic acid.

3. The process as claimed in claim 2, wherein said lower aliphatic carboxylic acid is acetic acid.

4. The process as claimed in claim 2, wherein said lower aliphatic carboxylic acid is formic acid.

5. A pharmaceutical composition for inhibiting catechol-O-methyl-transferase, said composition comprising a catechol-O-methyl-transferase inhibiting amount of the crystallographically essentially pure polymorphic form A of (E)-N,N-diethyl-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)acrylamide of claim 1 and a pharmaceutically acceptable carrier.

6. A method for inhibiting catechol-O-methyl -transferase in a patient, said method comprising administering a catechol-O-methyl-transferase inhibiting amount of the crystallographically essentially pure polymorphic form A of (E)-N,N-diethyl-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)acrylamide of claim 1, to a patient in need of such treatment.

7. A method for the treatment of Parkinson's Disease, said method comprising administering a catechol-O-methyl-transferase inhibiting amount of the crystallographically essentially pure polymorphic form A of (E)-N,N-diethyl-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)acrylamide of claim 1; and a sufficient amount of levodopa to treat Parkinson's disease, to a patient in need of such treatment.

8. The method as claimed in claim 7, further comprising administering a sufficient amount of a peripheral decarboxylase inhibitor to inhibit early dopamine formation.

9. The method as claimed in claim 8, wherein said peripheral decarboxylase inhibitor is carbidopa.

10. The method as claimed in claim 8, wherein said peripheral decarboxylase inhibitor is benserazide.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Mallinckrodt
Express Scripts
Julphar
Healthtrust
McKinsey
US Department of Justice
Argus Health
Daiichi Sankyo
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.